The Zhitong Finance App learned that Corning Jerry Pharmaceutical-B (09966) rose more than 7% in the afternoon. As of press release, it had risen 6.45% to HK$4.62, with a turnover of HK$114.666 million.
According to the news, Corning Jerry Pharmaceutical-B announced its 2023 annual results, with revenue of RMB 219 million, up 31.12% year on year; losses during the year were RMB 211 million, and losses narrowed 35.35% year over year. It is worth noting that in 2023, we achieved product revenue of 196 million yuan, an increase of 32.54% over the previous year.
According to the announcement, the increase in revenue mainly comes from Sichuan Silu Kangrui Pharmaceutical Co., Ltd. The Group and Siludi Pharmaceuticals signed a license agreement for the joint development and commercialization of KN035 in February 2016. It is worth noting that on January 24 of this year, Siludi Pharmaceuticals and Corning Jerry will grant Glenmark an exclusive license and re-authorization for KN035 (generic name: Envolizumab injection; trade name: Envida) oncology indications.